Iltefat Hamzavi, MD, describes the pathophysiology of hidradenitis suppurativa and associated comorbidities that are commonly seen in patients.
Video content above is prompted by the following question(s):
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
September 27th 2025The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.
Read More